What does the future of European healthcare look like?After the “stress test” of COVID, how can the sector create resilient, sustainable healthcare systems for the long Share XWhat does the future of European healthcare look like?https://pharmaphorum.com/patients/what-does-the-future-of-european-healthcare-look-like/
Consternation as NICE rejects Janssen MS drug PonvoryNICE has delivered its first verdict on NHS funding of Janssen’s oral multiple sclerosis drug Ponvory, and it’s Share XConsternation as NICE rejects Janssen MS drug Ponvoryhttps://pharmaphorum.com/news/consternation-as-nice-rejects-janssen-ms-drug-ponvory/
Joy as sickle cell patients get access to Novartis’ Adakveo after NICE rulingPeople living with sickle cell disease (SCD) in England and Wales will be able to get access to Share XJoy as sickle cell patients get access to Novartis’ Adakveo after NICE rulinghttps://pharmaphorum.com/news/joy-as-sickle-cell-patients-get-access-to-novartis-adakveo-after-nice-ruling/
NICE clears NHS use of Roche’s Tecentriq in bladder cancerNICE has recommended routine NHS access to Roche’s cancer immunotherapy Tecentriq for some bladder cancer patients, four years Share XNICE clears NHS use of Roche’s Tecentriq in bladder cancerhttps://pharmaphorum.com/news/nice-clears-nhs-use-of-roches-tecentriq-in-bladder-cancer/
Keytruda backed by NICE for late-stage oesophageal cancerMSD’s Keytruda has become the first immunotherapy cleared by NICE for previously-untreated patients with advanced oesophageal cancer, making Share XKeytruda backed by NICE for late-stage oesophageal cancerhttps://pharmaphorum.com/news/keytruda-backed-by-nice-for-late-stage-oesophageal-cancer/
NICE backs BioCryst’s Orladeyo for hereditary angioedemaBioCryst Pharma’s Orladeyo has been recommended by NICE as a treatment for the rare disease hereditary angioedema (HAE) Share XNICE backs BioCryst’s Orladeyo for hereditary angioedemahttps://pharmaphorum.com/news/nice-backs-biocrysts-orladeyo-for-hereditary-angioedema/
NICE changes its mind on J&J’s Erleada in prostate cancerNICE has reversed its position on Johnson & Johnson’s oral prostate cancer therapy Erleada in patients with hormone-relapsed Share XNICE changes its mind on J&J’s Erleada in prostate cancerhttps://pharmaphorum.com/news/nice-changes-its-mind-on-jjs-erleada-in-prostate-cancer/
NICE backs Cosentyx’ use in thousands of children with psoriasisNICE has recommended broadening NHS use of Novartis’ IL-17 inhibitor Cosentyx to include children aged six to 17 Share XNICE backs Cosentyx’ use in thousands of children with psoriasishttps://pharmaphorum.com/news/nice-backs-cosentyx-use-in-thousands-of-children-with-psoriasis/
NICE backs NHS use of Novartis’ cholesterol drug LeqvioNovartis’ cholesterol-lowering drug Leqvio will be made available on the NHS in England and Wales, and could help Share XNICE backs NHS use of Novartis’ cholesterol drug Leqviohttps://pharmaphorum.com/news/nice-backs-nhs-use-of-novartis-cholesterol-drug-leqvio/
